In Brief: Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Medtronic: Purchases worldwide manufacturing and distribution rights to Germany-based Tricumed's IP-20.1 fixed-rate and IP-35.1 selectable rate drug pumps and related accessories. The implantable pumps will complement Medtronic's SynchroMed pump, which is a higher-end device that can be reprogrammed after implantation through telemetry. Medtronic will continue selling the Tricumed pumps in Europe through Tricumed's distribution network but eventually plans to use its own direct European sales force...You may also be interested in...
Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: